U2Bio Co., Ltd.
U2Bio Co., Ltd. provides healthcare services in South Korea. The company also offers specimen testing services; digital healthcare services related to testing and health examinations; and bio-technology platforms. The company was founded in 2009 and is headquartered in Seoul, South Korea.
U2Bio Co., Ltd. (221800) - Total Assets
Latest total assets as of March 2025: ₩44.34 Billion KRW
Based on the latest financial reports, U2Bio Co., Ltd. (221800) holds total assets worth ₩44.34 Billion KRW as of March 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
U2Bio Co., Ltd. - Total Assets Trend (2022–2024)
This chart illustrates how U2Bio Co., Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
U2Bio Co., Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
U2Bio Co., Ltd.'s total assets of ₩44.34 Billion consist of 94.1% current assets and 5.9% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 36.7% |
| Accounts Receivable | ₩7.48 Billion | 16.6% |
| Inventory | ₩727.58 Million | 1.6% |
| Property, Plant & Equipment | ₩1.19 Billion | 2.6% |
| Intangible Assets | ₩1.02 Billion | 2.3% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2022–2024)
This chart illustrates how U2Bio Co., Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: U2Bio Co., Ltd.'s current assets represent 94.1% of total assets in 2024, an increase from 93.8% in 2022.
- Cash Position: Cash and equivalents constituted 36.7% of total assets in 2024, up from 0.0% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2022.
- Asset Diversification: The largest asset category is accounts receivable at 16.6% of total assets.
U2Bio Co., Ltd. Competitors by Total Assets
Key competitors of U2Bio Co., Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF
|
USA | $4.51 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
NSN Co. Ltd
KQ:031860
|
Korea | ₩60.96 Billion |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
U2Bio Co., Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - U2Bio Co., Ltd. generates 0.56x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - U2Bio Co., Ltd. is currently not profitable relative to its asset base.
U2Bio Co., Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.87 | 6.78 | 6.78 |
| Quick Ratio | 6.73 | 6.66 | 6.66 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩35.67 Billion | ₩ 36.82 Billion | ₩ 36.82 Billion |
U2Bio Co., Ltd. - Advanced Valuation Insights
This section examines the relationship between U2Bio Co., Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.93 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -8.6% |
| Total Assets | ₩44.98 Billion |
| Market Capitalization | $84.13 Million USD |
Valuation Analysis
Below Book Valuation: The market values U2Bio Co., Ltd.'s assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: U2Bio Co., Ltd.'s assets decreased by 8.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for U2Bio Co., Ltd. (2022–2024)
The table below shows the annual total assets of U2Bio Co., Ltd. from 2022 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩44.98 Billion | -8.57% |
| 2023-12-31 | ₩49.20 Billion | -3.58% |
| 2022-12-31 | ₩51.03 Billion | -- |